156 related articles for article (PubMed ID: 28713374)
1. The Selective Phosphoinoside-3-Kinase p110δ Inhibitor IPI-3063 Potently Suppresses B Cell Survival, Proliferation, and Differentiation.
Chiu H; Mallya S; Nguyen P; Mai A; Jackson LV; Winkler DG; DiNitto JP; Brophy EE; McGovern K; Kutok JL; Fruman DA
Front Immunol; 2017; 8():747. PubMed ID: 28713374
[TBL] [Abstract][Full Text] [Related]
2. The catalytic PI3K isoforms p110gamma and p110delta contribute to B cell development and maintenance, transformation, and proliferation.
Beer-Hammer S; Zebedin E; von Holleben M; Alferink J; Reis B; Dresing P; Degrandi D; Scheu S; Hirsch E; Sexl V; Pfeffer K; Nürnberg B; Piekorz RP
J Leukoc Biol; 2010 Jun; 87(6):1083-95. PubMed ID: 20200404
[TBL] [Abstract][Full Text] [Related]
3. Selective pharmacological inhibition of phosphoinositide 3-kinase p110delta opposes the progression of autoimmune diabetes in non-obese diabetic (NOD) mice.
Durand CA; Richer MJ; Brenker K; Graves M; Shanina I; Choi K; Horwitz MS; Puri KD; Gold MR
Autoimmunity; 2013 Feb; 46(1):62-73. PubMed ID: 23039284
[TBL] [Abstract][Full Text] [Related]
4. Selective inhibition of phosphoinositide 3-kinase p110α preserves lymphocyte function.
So L; Yea SS; Oak JS; Lu M; Manmadhan A; Ke QH; Janes MR; Kessler LV; Kucharski JM; Li LS; Martin MB; Ren P; Jessen KA; Liu Y; Rommel C; Fruman DA
J Biol Chem; 2013 Feb; 288(8):5718-31. PubMed ID: 23275335
[TBL] [Abstract][Full Text] [Related]
5. Ligand-selective signal transduction by two endogenous GnRH isoforms involves biased activation of the class I PI3K catalytic subunits p110β, p110γ, and p110δ in pituitary gonadotropes and somatotropes.
Pemberton JG; Stafford JL; Chang JP
Endocrinology; 2015 Jan; 156(1):218-30. PubMed ID: 25343277
[TBL] [Abstract][Full Text] [Related]
6. ETP-46321, a dual p110α/δ class IA phosphoinositide 3-kinase inhibitor modulates T lymphocyte activation and collagen-induced arthritis.
Aragoneses-Fenoll L; Montes-Casado M; Ojeda G; Acosta YY; Herranz J; Martínez S; Blanco-Aparicio C; Criado G; Pastor J; Dianzani U; Portolés P; Rojo JM
Biochem Pharmacol; 2016 Apr; 106():56-69. PubMed ID: 26883061
[TBL] [Abstract][Full Text] [Related]
7. A selective inhibitor of the p110delta isoform of PI 3-kinase inhibits AML cell proliferation and survival and increases the cytotoxic effects of VP16.
Billottet C; Grandage VL; Gale RE; Quattropani A; Rommel C; Vanhaesebroeck B; Khwaja A
Oncogene; 2006 Oct; 25(50):6648-59. PubMed ID: 16702948
[TBL] [Abstract][Full Text] [Related]
8. Selective inhibitors of phosphoinositide 3-kinase delta: modulators of B-cell function with potential for treating autoimmune inflammatory diseases and B-cell malignancies.
Puri KD; Gold MR
Front Immunol; 2012; 3():256. PubMed ID: 22936933
[TBL] [Abstract][Full Text] [Related]
9. p110δ PI3 kinase pathway: emerging roles in cancer.
Tzenaki N; Papakonstanti EA
Front Oncol; 2013; 3():40. PubMed ID: 23459844
[TBL] [Abstract][Full Text] [Related]
10. PI3K p110delta regulates T-cell cytokine production during primary and secondary immune responses in mice and humans.
Soond DR; Bjørgo E; Moltu K; Dale VQ; Patton DT; Torgersen KM; Galleway F; Twomey B; Clark J; Gaston JS; Taskén K; Bunyard P; Okkenhaug K
Blood; 2010 Mar; 115(11):2203-13. PubMed ID: 20081091
[TBL] [Abstract][Full Text] [Related]
11. p110δ phosphoinositide 3-kinase represses IgE switch by potentiating BCL6 expression.
Zhang TT; Makondo KJ; Marshall AJ
J Immunol; 2012 Apr; 188(8):3700-8. PubMed ID: 22422878
[TBL] [Abstract][Full Text] [Related]
12. Conformational disruption of PI3Kδ regulation by immunodeficiency mutations in
Dornan GL; Siempelkamp BD; Jenkins ML; Vadas O; Lucas CL; Burke JE
Proc Natl Acad Sci U S A; 2017 Feb; 114(8):1982-1987. PubMed ID: 28167755
[TBL] [Abstract][Full Text] [Related]
13. Targeting PI3Kδ and PI3Kγ signalling disrupts human AML survival and bone marrow stromal cell mediated protection.
Pillinger G; Loughran NV; Piddock RE; Shafat MS; Zaitseva L; Abdul-Aziz A; Lawes MJ; Bowles KM; Rushworth SA
Oncotarget; 2016 Jun; 7(26):39784-39795. PubMed ID: 27174919
[TBL] [Abstract][Full Text] [Related]
14. PI3K pan-inhibition impairs more efficiently proliferation and survival of T-cell acute lymphoblastic leukemia cell lines when compared to isoform-selective PI3K inhibitors.
Lonetti A; Cappellini A; Spartà AM; Chiarini F; Buontempo F; Evangelisti C; Evangelisti C; Orsini E; McCubrey JA; Martelli AM
Oncotarget; 2015 Apr; 6(12):10399-414. PubMed ID: 25871383
[TBL] [Abstract][Full Text] [Related]
15. Germline-activating mutations in
Avery DT; Kane A; Nguyen T; Lau A; Nguyen A; Lenthall H; Payne K; Shi W; Brigden H; French E; Bier J; Hermes JR; Zahra D; Sewell WA; Butt D; Elliott M; Boztug K; Meyts I; Choo S; Hsu P; Wong M; Berglund LJ; Gray P; O'Sullivan M; Cole T; Holland SM; Ma CS; Burkhart C; Corcoran LM; Phan TG; Brink R; Uzel G; Deenick EK; Tangye SG
J Exp Med; 2018 Aug; 215(8):2073-2095. PubMed ID: 30018075
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of PI3K p110δ activity reduces IgE production in IL-4 and anti-CD40 stimulated human B cell cultures.
Cutrina-Pons A; De Sa A; Fear DJ; Gould HJ; Ramadani F
Immunology; 2023 Dec; 170(4):483-494. PubMed ID: 37530226
[TBL] [Abstract][Full Text] [Related]
17. The Therapeutic Potential for PI3K Inhibitors in Autoimmune Rheumatic Diseases.
Banham-Hall E; Clatworthy MR; Okkenhaug K
Open Rheumatol J; 2012; 6():245-58. PubMed ID: 23028409
[TBL] [Abstract][Full Text] [Related]
18. Regulation of breast cancer cell chemotaxis by the phosphoinositide 3-kinase p110delta.
Sawyer C; Sturge J; Bennett DC; O'Hare MJ; Allen WE; Bain J; Jones GE; Vanhaesebroeck B
Cancer Res; 2003 Apr; 63(7):1667-75. PubMed ID: 12670921
[TBL] [Abstract][Full Text] [Related]
19. T and B-cell signaling in activated PI3K delta syndrome: From immunodeficiency to autoimmunity.
Preite S; Gomez-Rodriguez J; Cannons JL; Schwartzberg PL
Immunol Rev; 2019 Sep; 291(1):154-173. PubMed ID: 31402502
[TBL] [Abstract][Full Text] [Related]
20. p110gamma and p110delta phosphoinositide 3-kinase signaling pathways synergize to control development and functions of murine NK cells.
Tassi I; Cella M; Gilfillan S; Turnbull I; Diacovo TG; Penninger JM; Colonna M
Immunity; 2007 Aug; 27(2):214-27. PubMed ID: 17723215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
